Next Article in Journal
Misdiagnosis of Acute Limb Ischemia from Non-Vascular Specialists Results in a Delayed Presentation and Negatively Affects Patients’ Outcomes
Previous Article in Journal
Outcomes in Acute Decompensated Congestive Heart Failure Admissions with Chronic Liver Disease: A Nationwide Analysis Using the National Inpatient Sample
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Correlation Between Blood Coagulation Profile and Viscosity: Clinical Laboratory Observational Study

by
Ezekiel U. Nwose
1,* and
Phillip T. Bwititi
2
1
School of Health & Medical Sciences, University of Southern Queensland, Toowoomba, QLD 4350, Australia
2
School of Dentistry & Medical Sciences, Charles Sturt University, Wagga Wagga, NSW 2650, Australia
*
Author to whom correspondence should be addressed.
Med. Sci. 2025, 13(1), 20; https://doi.org/10.3390/medsci13010020
Submission received: 31 December 2024 / Revised: 31 January 2025 / Accepted: 13 February 2025 / Published: 16 February 2025
(This article belongs to the Section Cardiovascular Disease)

Abstract

:
Whole blood viscosity is a test for blood stasis and is an ideal evidence-based pathology parameter that is largely undervalued and retrogressing in clinical utilization. Coagulation profiles as indices of haemostasis are available but limited to central or referral laboratories and often involve long turn-around time. It is therefore important to study the correlation between the index of stasis and indices of haemostasis. Objective: To investigate the correlation of index of stasis with indices of haemostasis. Method: The clinical laboratory observational research method, using archived pathology data. Indices of haemostasis including activated partial thromboplastin time (APTT) and prothrombin time (PT), the international normalization ratio (INR), and plasma D-dimer were evaluated. On the other hand, the index of blood stasis used was the estimated whole blood viscosity (eWBV) and derived haematocrit and serum protein levels. All (N = 193) tests were collected within a calendar year from the same pathology service, and further, for the correlation, each set of variables from the same blood sample collection was used. Results: The haemostasis data are skewed (skewness > 2.0), while eWBV and platelet count are normal (skewness < 2.0). Haemostasis indices have an inverse association with eWBV (p < 0.001). The concordance and correlation of eWBV with platelet count is positive, weak, and significant (p < 0.001), but negative and negligible with PT and APTT. Conclusion: There are limitations to the possible correlation between eWBV and haemostasis indices. However, haemostasis indices have inverse associations with eWBV, and the latter can aid in the evaluation of haemostasis hence could be utilized as an alternative or complementary test to haemostasis tests. Research may normalize skewed data to obtain better correlation; therefore, further study is required to advance discourse, giving cognizance to clinical practice.

1. Introduction

Haemostasis has been an established medical concept, and the pathophysiology continues to constitute a clinical management challenge [1,2,3]. In the last 30 years, medical science research has demonstrated a possible relationship between haemostasis and dyslipidaemia [4], antiplatelet medication [5,6,7,8], and the trios of vasculopathy known as Virchow’s triad [9]. However, there is still a need for the accurate and validated prediction of bleeding risk [10,11].
It suffices to say haemostasis is a physiological balance between fibrinolysis and coagulation, or a central point of preventing bleeding and thrombosis. Hence, pathology tests in the clinical management of patients with haemostasis comprise mainly full blood count and coagulation profiles, especially including but not limited to platelet count, prothrombin time, and activated partial thromboplastin time. In more resourced settings and research centres, the plasma D-dimer test is carried out to assess the magnitude of fibrinolysis that in turn reflects the extent of coagulation [12]. It is important to emphasize that the plasma D-dimer test has been of interest but limited by problems of affordances [13,14,15].
In defining haemostasis as a balance between coagulation and fibrinolysis, there is an associated pathophysiology on either side of the continuum including bleeding and thrombosis. In the concept of Virchow’s triad, the pathophysiology is underpinned by endothelial dysfunction, hypercoagulation, and blood pooling or stasis [9], whereby the clinical pathology parameters are homocysteine, plasma D-dimer, and blood viscosity, respectively [16]. Although, endothelial dysfunction impacts blood stasis, hence, homocysteine is sometimes measured as a factor that affects blood viscosity [17]. None of these pathology tests are accessible in rural and remote settings, especially in low–mid-income countries where healthcare resources are limited.
Estimated whole blood viscosity (eWBV) is one test that has been advanced to extrapolate the value from routine haematocrit and serum protein [18]. Indeed, the eWBV dates back over 30 years [19] and has undergone validation processes including previous studies that have demonstrated the applicability of the medical science theory in diabetes [20], as well as proof of concept [16,17,21,22]. Nevertheless, the blood viscosity test is still overlooked in clinical practice [23,24,25], perhaps due to limited interpretation that tends to focus on hyperviscosity syndrome [26,27,28,29]. It is interesting to note that even where the test has been performed, albeit in a reference laboratory [30], the service has seized because it is erroneously viewed to be of little or no value [29]. Thus, the implication is that an established medical science has retrogressed.
Therefore, there is a need to advance the knowledge with a view to reintroduce blood viscosity testing into clinical practice. Motivated by recent reports on gender differences in coagulation parameters [31], and our previous reports [16,21,22,32]; the objective of this study is to briefly evaluate the correlation between the laboratory parameters of haemostasis and blood stasis (eWBV).

2. Materials and Methods

Design: This was a clinical laboratory observational study. Evaluation was designed to include descriptive approach, as well as comparisons and correlation. The correlation evaluation was performed to observe epidemiological factors [33]. The study design can also be described as a cross-sectional observation or clinical audit, with a small cohort evaluation using archived clinical pathology data.
Setting: Pathology data from regional New South Wales of Australia, as previously published [16,21,22].
Data variables: Parameters of haemostasis were limited to prothrombin time (PT) and activated partial thromboplastin time (APTT) as well as plasma D-dimer as in the study of He et al. [31].
Inclusion criteria: The selection criteria were limited to cases with a complete set of results for haematocrit, serum protein, and plasma D-dimer, as well as APTT, PT INR, and platelet count.
Method of eWBV measurement: The blood viscosity in this study was determined by the extrapolation method, as previously published [34]. It is pertinent to note that this eWBV option was compared with the digital method used in a reference laboratory [30].
Statistical analysis: Data were analyzed to check for differences in age and gender groups in consideration of other studies [26]. Considering the likelihood of fibrinolysis impacting pre-menopausal women [35] and previous observations in our study [16], the D-dimer variable was used to categorize data into [yes] and [no] dichotomous groups to compare the changes in eWBV with haemostasis indices (APTT, PT, and INR) and platelet count. Lastly, the levels of correlations among the eWBV, APTT, PT INR, and platelet count were evaluated using the Pearson correlation method.
Limitations: Cognizance was given to the sample size being considered relatively small. Therefore, “practical strategies for getting the most out of data when sample size is small” were adopted [36]. This included the measurement of theoretically strong indicators (APTT, D-dimer, and PT), as well as including a covariate (INR, another independent variable) that has been previously determined to be strongly related to the eWBV.

3. Results

For this cross-sectional study, a sample size of N = 193 satisfied the inclusion criteria. Descriptive statistics show that haemostasis data are asymmetrically distributed (kurtosis > 3.0 and skewness > 2.0), while the eWBV is symmetrical (Table 1).
Comparison of the variables between stratified age groups: Haemostasis variables and platelet count decreased at the 31–45 years of age group compared to the ≤30 years of age group, but increased thereafter, and only APTT achieved statistical significance (p < 0.04). The opposite is the case with serum proteins and eWBV in terms of directional change, but with a greater level of significance (Table 2).
Comparison of gender groups: The haemostasis variables are higher in women but not statistically significant, except for platelet count (p < 0.02). The opposite is the case with serum proteins and eWBV in terms of directional change and with a greater level of statistical significance (Table 3).
Comparison of eWBV and haemostasis variables between dichotomous D-dimer groups: APTT is statistically significantly higher among those with the positive group (p < 0.03). Conversely, eWBV and its indices are significantly lower (p < 0.001) compared to the negative group. The average age is noted to be higher with the positive D-dimer group (p < 0.001, Table 4).
Correlation and cohort analyses: It is observed that eWBV is moderately positively correlated with platelet count (r −0.26, p < 0.001), but negligibly negative with the haemostasis indices (r < 0.20, Table 5). Among the data, 16/193 comprised a cohort of n = 8 record numbers with repeated tests (Table 6). A concordance review of the small cohort shows a 100% association between eWBV and platelet count. The concordance of eWBV was in 3/8 and varied in the other 5/8.

4. Discussion

Table 1 shows that haemostasis data are quite asymmetrically distributed (kurtosis > 3.0 and skewness > 2.0), while eWBV and platelet counts are symmetrical. The evaluation of correlation for normally distributed data such as eWBV and platelet counts would require Pearson’s method. The asymmetric haemostasis indices would require log transformation, which can be conducted in research but not in a routine clinical pathology practice.
It is common in clinical practice that some data are asymmetric [37], and given that data are interpreted as they are in clinical practice, correlations between eWBV and haemostasis indices may be spurious. In the stratified age groups, haemostasis variables decreased while eWBV increased, and the latter showed a greater level of statistical significance (Table 2). There is indication of inverse association subject to verification with correlation analysis.
A previous study has reported the inverse relation of eWBV with INR [32]. What this report contributes is that similar inverse relationships may be occurring between eWBV and haemostasis indices (PT and APTT). The algorithmic eWBV test may be an alternative or complementary test to PT and APTT, especially where the turn-around time of the haemostasis test is a consideration.
The levels of haemostasis indices are insignificantly lower in men, while blood viscosity is significantly higher in men, compared to women (Table 3). The inverse relationship between eWBV and haemostasis indices is noteworthy given that fibrinolysis is lower among men than albeit pre-menopausal women [35]. Haemostasis is physiological balanced between coagulation and fibrinolysis, and it suffices that the lower rate of fibrinolysis explains the lower haemostasis biomarkers in men.
This contributes empirical data to support the higher levels of PT and APTT in women than men. Considering menstrual cycles and lower haematocrit in women, it is expected that eWBV would be higher in men [38]. Hence, the tendency for a higher risk of venous thrombosis among men than women [39,40]. On the other hand, there is reported potential of blood stasis being higher among women [41]. This may be a confound risk of the higher fibrinolysis being associated with greater plasma D-dimer in women and lower among men [42].
In the dichotomous D-dimer groups, APTT is significantly higher among those with the positive group (p < 0.03), while age as well as eWBV and its indices are significantly lower (p < 0.001), relative to the group that tested negative for D-dimer. Platelet count is also lower in the positive D-dimer group, although statistical significance is not achieved in this dataset (Table 4). This observation further reaffirms preceding observations, indicating inverse relations.
There is evidence that positive D-dimer is associated with anemia [43], and further, enhanced haemostasis activities indicated by increased plasma D-dimer are associated with thrombocytopenia [44]. Therefore, there is no gainsaying that blood viscosity could be inversely related with the haemostasis physiological process. Further, higher APTT is associated with positive D-dimer in this report, and this observation agrees with the report of another observational study that plasma D-dimer may increase with APTT and PT in certain circumstances [45]. Yet, APTT is expected to decrease, while D-dimer increases [46]. There is the idea that APTT can complement D-dimer in clinical management [46,47], hence, this report advances that eWBV is a valuable pathology biomarker to consider.
The correlation analysis confirms the preceding observations, i.e., that blood viscosity is negatively associated with haemostasis indices but positively associated with platelet count (Table 5). This is further confirmed by concordance review, as eWBV consistently increased with platelet count and vice versa in the subset of data (Table 6). Perhaps, it can be inferred and incontrovertible to note that while ‘stasis’ is a suffix in haemostasis, and the two terms are related, there is little difference in physiological phenomena, hence, laboratory tests that specifically evaluate for the two phenomena. It is also noteworthy that eWBV and platelet count are symmetrical data, while the haemostasis profiles are skewed; therefore, there is a strong limitation and reason for negligible correlation.
Antiplatelet therapy and anticoagulant medications are blood thinners in cardiology management, but the mechanisms of action are different. Anticoagulant is focused on the coagulation cascade and blood clot such as warfarin actin on the vitamin K pathway, while the antiplatelet therapy works on platelet function and stasis [48]. Blood viscosity is more specifically related to blood pooling; hence, it correlates with blood flow [49].

Significance in Clinical Practice

There are empirical data showing that INR and WBV are inversely related [32,49]. This report contributes additional empirical data on other test parameters of haemostasis. To our knowledge, this is the first observational study to focus on the correlation between blood viscosity and the clinical pathology-based tests of haemostasis. More importantly, this report highlights the limitation of the correlation. There may be a temptation in research to log-normalize the skewed data, but clinical practice should be the guide.
It is also pertinent to highlight that the issue of bleeding remains a concern [50,51,52]. The therapeutic management still constitutes a dilemma [53,54,55,56], hence the continued research interest [57]. The significance for clinical practice cuts across several health issues involving cardiovascular complications, including but not limited to diabetes and kidney disease [12,57]. It has long been known that blood viscosity can be used to assess polycythemia complications [58], including but not limited to retinopathy [59].
Therefore, beyond the contribution of empirical data to advance the medical science of blood stasis, this report advances eWBV as an alternative or complimentary pathology test applicable to a wide range of disease management. For instance, the thromboembolic risk score assessment model is still questionable, hence limited in usage [60]. Further studies would be necessary to compare eWBV as a hemorheology predictor versus the risk score model in the assessment of future thromboembolic events.

5. Conclusions

This study identified haemostasis management as one area of clinical practice where laboratory methods would benefit from eWBV as a pathology test. The correlations between eWBV and the haemostasis indices (APTT, INR, and/or PT) constitute an advancement in knowledge regarding the science for improved healthcare practice. The method can be adopted and replicated. Thus, the relevance lies in the re-evaluation of eWBV for adoption and utilization as either an alternative or complementary test to the profile of APTT, INR, and/or PT.

Author Contributions

E.U.N. conceptualized the work, requested the data with ethics approval, performed the statistical analysis, plus the interpretation of data, and initiated the draft manuscript. P.T.B. contributed to the conceptualization of the work, the interpretation of data, and the writing of the main manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and granted a waiver to use de-identified data by the SWPS of NSW Pathology.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data generated or analyzed during this study are included in this published article.

Acknowledgments

The archived clinical pathology data are from the Southwest Pathology Service (SWPS) of the New South Wales pathology service, as previously published. This report adds to a growing series, and it is parallel with other ongoing analyses.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bateman, R.M.; Sharpe, M.D.; Jagger, J.E.; Ellis, C.G.; Solé-Violán, J.; López-Rodríguez, M.; Herrera-Ramos, E.; Ruíz-Hernández, J.; Borderías, L.; Horcajada, J.; et al. 36th International Symposium on Intensive Care and Emergency Medicine: Brussels, Belgium, 15–18 March 2016. Crit. Care 2016, 20 (Suppl. S2), 94. [Google Scholar] [PubMed]
  2. Forsyth, A.L.; Giangrande, P.; Hay, C.R.; Kenet, G.; Kessler, C.M.; Knöbl, P.N.; Llinás, A.; Santagostino, E.; Young, G. Difficult clinical challenges in haemophilia: International experiential perspectives. Haemophilia 2012, 18 (Suppl. S5), 39–45. [Google Scholar] [CrossRef] [PubMed]
  3. Briane, A.; Horvais, V.; Sigaud, M.; Trossaërt, M.; Drillaud, N.; Ternisien, C.; Fouassier, M.; Babuty, A. Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case report. EJHaem 2024, 5, 964–970. [Google Scholar] [CrossRef]
  4. Ambrosi, P.; Juhan-Vague, I. Dyslipidemia, lipid lowering drugs and thrombosis. Arch. Mal. Coeur Vaiss. 1995, 88, 1641–1645. [Google Scholar]
  5. Sonksen, J.R.; Kong, K.L.; Holder, R. Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br. J. Anaesth. 1999, 82, 360–365. [Google Scholar] [CrossRef]
  6. Rosenson, R.S.; Wolff, D.; Green, D.; Boss, A.H.; Kensey, K.R. Aspirin. Aspirin does not alter native blood viscosity. J. Thromb. Haemost. 2004, 2, 340–341. [Google Scholar] [PubMed]
  7. Cattaneo, M. Response variability to clopidogrel: Is tailored treatment, based on laboratory testing, the right solution? J. Thromb. Haemost. 2012, 10, 327–336. [Google Scholar] [CrossRef]
  8. Bhatt, D.L.; Eikelboom, J.W.; Connolly, S.J.; Steg, P.G.; Anand, S.S.; Verma, S.; Branch, K.R.H.; Probstfield, J.; Bosch, J.; Shestakovska, O.; et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease. Circulation 2020, 141, 1841–1854. [Google Scholar] [CrossRef] [PubMed]
  9. Lowe, G.D. Virchow’s triad revisited: Abnormal flow. Pathophysiol. Haemost. Thromb. 2003, 33, 455–457. [Google Scholar] [CrossRef] [PubMed]
  10. Roldan, V.; Marin, F.; Manzano-Fernandez, S.; Gallego, P.; Vilchez, J.A.; Valdes, M.; Vicente, V.; Lip, G.Y. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J. Am. Coll. Cardiol. 2013, 62, 2199–2204. [Google Scholar] [CrossRef]
  11. Fan, K.; Xiao, Y.; Xue, A.; Zhou, J. Clinical outcomes, management, healthcare resource utilization, and cost according to the CHA(2)DS(2)-VASc scores in Asian patients with nonvalvular atrial fibrillation. Int. J. Cardiol. 2024, 417, 132496. [Google Scholar] [CrossRef]
  12. Nwose, E.U.; Richards, R.S.; Jelinek, H.F.; Kerr, P.G. D-dimer identifies stages in the progression of diabetes mellitus from family history of diabetes to cardiovascular complications. Pathology 2007, 39, 252–257. [Google Scholar] [CrossRef] [PubMed]
  13. Belkhir, D.; Blibech, H.; Kaabi, L.; Miladi, S.; Jebali, M.A.; Daghfous, J.; Mehiri, N.; Laatar, A.; Ben Salah, N.; Snene, H.; et al. Laboratory findings predictive of critical illness in hospitalized COVID-19 patients in Tunisia. F1000Research 2024, 13, 918. [Google Scholar] [CrossRef]
  14. Corrêa, H.L.; Deus, L.A.; Nascimento, D.D.C.; Rolnick, N.; Neves, R.V.P.; Reis, A.L.; de Araújo, T.B.; Tzanno-Martins, C.; Tavares, F.S.; Neto, L.S.S.; et al. Concerns about the application of resistance exercise with blood-flow restriction and thrombosis risk in hemodialysis patients. J. Sport Health Sci. 2024, 13, 548–558. [Google Scholar] [CrossRef] [PubMed]
  15. Piech, P.; Haratym, M.; Borowski, B.; Węgłowski, R.; Staśkiewicz, G. Beyond the fractures: A comprehensive Comparative analysis of Affordable and Accessible laboratory parameters and their coefficients for prediction and Swift confirmation of pulmonary embolism in high-risk orthopedic patients. Pract. Lab. Med. 2024, 40, e00397. [Google Scholar] [CrossRef] [PubMed]
  16. Nwose, E.U. Whole blood viscosity assessment issues II: Prevalence in endothelial dysfunction and hypercoagulation. N. Am. J. Med. Sci. 2010, 2, 252–257. [Google Scholar]
  17. Wi, M.; Kim, Y.; Kim, C.H.; Lee, S.; Bae, G.S.; Leem, J.; Chu, H. Effectiveness and safety of Fufang Danshen Dripping Pill (Cardiotonic Pill) on blood viscosity and hemorheological factors for cardiovascular event prevention in patients with type 2 diabetes mellitus: Systematic review and meta-analysis. Medicina 2023, 59, 1730. [Google Scholar] [CrossRef] [PubMed]
  18. Tamariz, L.J.; Young, J.H.; Pankow, J.S.; Yeh, H.-C.; Schmidt, M.I.; Astor, B.; Brancati, F.L. Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: The atherosclerosis risk in communities (ARIC) study. Am. J. Epidemiol. 2008, 168, 1153–1160. [Google Scholar] [CrossRef]
  19. Muldoon, M.F.; Herbert, T.B.; Patterson, S.M.; Kameneva, M.; Raible, R.; Manuck, S.B. Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. Arch. Intern. Med. 1995, 155, 615–620. [Google Scholar] [CrossRef] [PubMed]
  20. Nwose, E.U.; Richards, R.S.; McDonald, S.; Jelinek, H.F.; Kerr, P.G.; Tinley, P. Assessment of diabetic macrovascular complications: A prediabetes model. Br. J. Biomed. Sci. 2010, 67, 59–66. [Google Scholar] [CrossRef] [PubMed]
  21. Nwose, E.U.; Butkowski, E.G. Algorithm for whole blood viscosity: Implication for antiplatelet bleeding risk assessment. Aust. J. Med. Sci. 2013, 34, 50–55. [Google Scholar]
  22. Nwose, E.U.; Bwititi, P.T. Whole blood viscosity: Affordances and re-evaluation of sensitivity and specificity for clinical use. Int. J. Biol. Lab. Sci. 2022, 11, 96–103. [Google Scholar]
  23. Cakmak, G.; Alkan, F.A.; Korkmaz, K.; Saglam, Z.A.; Karis, D.; Yenigun, M.; Ercan, M. Blood viscosity as a forgotten factor and its effect on pulmonary flow. Transl. Respir. Med. 2013, 1, 3. [Google Scholar] [CrossRef] [PubMed]
  24. Ozcan Cetin, E.H.; Cetin, M.S.; Canpolat, U.; Kalender, E.; Topaloglu, S.; Aras, D.; Aydogdu, S. The forgotten variable of shear stress in mitral annular calcification: Whole blood viscosity. Med. Princ. Pract. 2015, 24, 444–450. [Google Scholar] [CrossRef] [PubMed]
  25. Celik, T.; Balta, S.; Ozturk, C.; Iyisoy, A. Whole blood viscosity and cardiovascular diseases: A forgotten old player of the game. Med. Princ. Pract. 2016, 25, 499–500. [Google Scholar] [CrossRef]
  26. Paisey, R.B.; Harkness, J.; Hartog, M.; Chadwick, T. The effect of improvement in diabetic control on plasma and whole blood viscosity. Diabetologia 1980, 19, 345–349. [Google Scholar] [CrossRef]
  27. Zarkovic, M.; Kwaan, H.C. Correction of hyperviscosity by apheresis. Semin. Thromb. Hemost. 2003, 29, 535–542. [Google Scholar] [PubMed]
  28. Perez Rogers, A.; Estes, M. Hyperviscosity syndrome. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2023. [Google Scholar]
  29. Hyperviscosity Syndrome. Available online: https://www.rcpa.edu.au/Manuals/RCPA-Manual/Clinical-Presentations-and-Diagnoses/H/Hyperviscosity-syndrome (accessed on 22 August 2022).
  30. Nwose, E.U.; Richards, R.S. Whole blood viscosity issue VIII: Comparison of extrapolation method with diagnostic digital viscometer. N. Am. J. Med. Sci. 2011, 3, 333–335. [Google Scholar] [CrossRef] [PubMed]
  31. He, M.; Ye, J.; Zheng, W.; Qiao, P.; Gu, H.; Qin, W.; He, X. The impact of gender differences on the clinical characteristics of critically ill patients with venous thromboembolism: A retrospective, observational study. Medicine 2024, 103, e38423. [Google Scholar] [CrossRef]
  32. Nwose, E.U.; Cann, N.G.; Butkowski, E. Whole blood viscosity assessment issues III: Association with international normalized ratio and thrombocytopenia. N. Am. J. Med. Sci. 2010, 2, 301–305. [Google Scholar]
  33. Lau, F. Chapter 12 Methods for Correlational Studies. In Handbook of eHealth Evaluation: An Evidence-Based Approach [Internet]; Lau, F., Kuziemsky, C., Eds.; University of Victoria: Victoria, BC, Canada, 2017. [Google Scholar]
  34. Nwose, E.U. CARDIOVASCULAR RISK ASSESSMENT AND SUPPORT TECHNIQUES: Whole blood viscosity assessment issues I: Extrapolation chart and reference values. N. Am. J. Med. Sci. 2010, 2, 165–169. [Google Scholar] [PubMed]
  35. Hill, A.M.; Stewart, P.W.; Fung, M.K.; Kris-Etherton, P.M.; Ginsberg, H.N.; Tracy, R.P.; Pearson, T.A.; Lefevre, M.; Reed, R.G.; Elmer, P.J.; et al. Monthly haemostatic factor variability in women and men. Eur. J. Clin. Investig. 2014, 44, 309–318. [Google Scholar] [CrossRef] [PubMed]
  36. Hopkin, C.R.; Hoyle, R.H.; Gottfredson, N.C. Maximizing the yield of small samples in prevention research: A review of general strategies and best practices. Prev. Sci. 2015, 16, 950–955. [Google Scholar] [CrossRef] [PubMed]
  37. Nandy, A.; Basu, A.; Ghosh, A. Robust inference for skewed data in health sciences. J. Appl. Stat. 2022, 49, 2093–2123. [Google Scholar] [CrossRef] [PubMed]
  38. Bryk, A.H.; Siudut, J.; Broniatowska, E.; Bagoly, Z.; Baráth, B.; Katona, É.; Undas, A. Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes. Thromb. Res. 2020, 185, 55–62. [Google Scholar] [CrossRef]
  39. Cushman, M. Epidemiology and risk factors for venous thrombosis. Semin. Hematol. 2007, 44, 62–69. [Google Scholar] [CrossRef]
  40. Roach, R.E.J.; Cannegieter, S.C.; Lijfering, W.M. Differential risks in men and women for first and recurrent venous thrombosis: The role of genes and environment. J. Thromb. Haemost. 2014, 12, 1593–1600. [Google Scholar] [CrossRef]
  41. Xiaoying, Z.; Shengwen, Y.; Jintao, O.; Zhuo, W.; Guangrong, W.; Yue, L. Screening influencing factors of blood stasis constitution in traditional Chinese medicine. Digit. Chin. Med. 2022, 5, 169–177. [Google Scholar] [CrossRef]
  42. Kain, K.; Carter, A.M.; Bamford, J.M.; Grant, P.J.; Catto, A.J. Gender differences in coagulation and fibrinolysis in white subjects with acute ischemic stroke. J. Thromb. Haemost. 2003, 1, 390–392. [Google Scholar] [CrossRef] [PubMed]
  43. Helin, T.A.; Lemponen, M.; Lahtiharju, T.; Koskinen, M.; Lassila, R.; Joutsi-Korhonen, L. Anaemia and enhancement of coagulation are associated with severe COVID-19 infection. Scand. J. Clin. Lab. Investig. 2021, 81, 653–660. [Google Scholar] [CrossRef] [PubMed]
  44. Sjöström, A.; Wersäll, J.D.; Warnqvist, A.; Farm, M.; Magnusson, M.; Oldner, A.; Ågren, A.; Antovic, J.; Bruzelius, M. Platelet count rose while D-dimer levels Dropped as deaths and thrombosis declined—An observational study on anticoagulation shift in COVID-19. Thromb. Haemost. 2021, 121, 1610–1621. [Google Scholar] [CrossRef] [PubMed]
  45. Long, H.; Nie, L.; Xiang, X.; Li, H.; Zhang, X.; Fu, X.; Ren, H.; Liu, W.; Wang, Q.; Wu, Q. D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. BioMed Res. Int. 2020, 2020, 6159720. [Google Scholar] [CrossRef]
  46. Habe, K.; Wada, H.; Mizutani, K.; Matsushima, Y.; Kondo, M.; Yamanaka, K. The clinical significance of a shortened activated partial thromboplastin time in patients with connective tissue disease. Clin. Rheumatol. 2021, 40, 4675–4683. [Google Scholar] [CrossRef]
  47. Wannamethee, S.G.; Papacosta, O.; Lennon, L.; Whincup, P.H.; Rumley, A.; Lowe, G.D.O. Haematological variables and risk of future venous thromboembolism in the British Regional Heart Study on men. Combined D-dimer and APTT as a predictive test for thromboembolism? Br. J. Haematol. 2022, 198, 587–594. [Google Scholar] [CrossRef]
  48. Shantsila, E.; Lip, G.Y. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. Cochrane Database Syst. Rev. 2016, 9, Cd003333. [Google Scholar] [CrossRef]
  49. Almarshad, H.A.; Hassan, F.M. Alterations in blood coagulation and viscosity among young male cigarette smokers of Al-Jouf region in Saudi Arabia. Clin. Appl. Thromb. Hemost. 2016, 22, 386–389. [Google Scholar] [CrossRef] [PubMed]
  50. Calori, S.; Comisi, C.; Mascio, A.; Fulchignoni, C.; Pataia, E.; Maccauro, G.; Greco, T.; Perisano, C. Overview of ankle arthropathy in hereditary hemochromatosis. Med. Sci. 2023, 11, 51. [Google Scholar] [CrossRef]
  51. Jones, A.; Al-Horani, R.A. Venous thromboembolism prophylaxis in major orthopedic surgeries and Factor XIa inhibitors. Med. Sci. 2023, 11, 49. [Google Scholar] [CrossRef] [PubMed]
  52. Pélieu, I.; Kull, C.; Walder, B. Prehospital and emergency care in adult patients with acute traumatic brain injury. Med. Sci. 2019, 7, 12. [Google Scholar] [CrossRef]
  53. Dunning, J.; Versteegh, M.; Fabbri, A.; Pavie, A.; Kolh, P.; Lockowandt, U.; Nashef, S.A.M. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg. 2008, 34, 73–92. [Google Scholar] [CrossRef] [PubMed]
  54. Furie, K.L.; Kasner, S.E.; Adams, R.J.; Albers, G.W.; Bush, R.L.; Fagan, S.C.; Halperin, J.L.; Johnston, S.C.; Katzan, I.; Kernan, W.N.; et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011, 42, 227–276. [Google Scholar] [CrossRef] [PubMed]
  55. Mitra, B.; Jorgensen, M.; Reade, M.C.; Keegan, A.; Holley, A.; Farmer, S.; Harvey, N.; Winearls, J.; Parr, M.; French, C.J. Patient blood management guideline for adults with critical bleeding. Med. J. Aust. 2024, 220, 211–216. [Google Scholar] [CrossRef] [PubMed]
  56. Rossaint, R.; Afshari, A.; Bouillon, B.; Cerny, V.; Cimpoesu, D.; Curry, N.; Duranteau, J.; Filipescu, D.; Grottke, O.; Grønlykke, L.; et al. The European guideline on management of major bleeding and coagulopathy following trauma: Sixth edition. Crit. Care 2023, 27, 80. [Google Scholar] [CrossRef] [PubMed]
  57. Gois, P.H.F.; McIntyre, D.; Ratanjee, S.; Pelecanos, A.; Scuderi, C.; Janoschka, C.L.; Summers, K.; Wu, H.; Elford, B.; Ranganathan, D.; et al. Hemodialysis without systemic anticoagulation: A randomized controlled trial to evaluate five strategies in patients at a high risk of bleeding. Med. Sci. 2024, 12, 38. [Google Scholar] [CrossRef]
  58. Tremblay, J.C.; Coombs, G.B.; Howe, C.A.; Vizcardo-Galindo, G.A.; Figueroa-Mujíca, R.J.; Bermudez, D.; Tymko, M.M.; Villafuerte, F.C.; Ainslie, P.N.; Pyke, K.E. Global Reach 2018: Reduced flow-mediated dilation stimulated by sustained increases in shear stress in high-altitude excessive erythrocytosis. Am. J. Physiol. Heart Circ. Physiol. 2019, 317, H991–H1001. [Google Scholar] [CrossRef]
  59. Foulds, W.S. 50th Bowman lecture. ‘Blood is thicker than water’. Some haemorheological aspects of ocular disease. Eye 1987, 1 Pt 3, 343–363. [Google Scholar] [CrossRef] [PubMed]
  60. Häfliger, E.; Kopp, B.; Darbellay Farhoumand, P.; Choffat, D.; Rossel, J.B.; Reny, J.L.; Aujesky, D.; Méan, M.; Baumgartner, C. Risk assessment models for venous thromboembolism in medical inpatients. JAMA Netw. Open 2024, 7, e249980. [Google Scholar] [CrossRef] [PubMed]
Table 1. Descriptive statistics of dataset.
Table 1. Descriptive statistics of dataset.
PROTHCTeWBVINRPTAPTTPLTAge
Mean68.240.3815.861.3815.8530.65223.857.62
Standard Error0.870.000.170.050.560.737.131.52
Median690.38916.171.1132723461
Mode720.41716.501.1122729278
Standard Deviation12.080.062.390.687.7510.1398.7721.12
Sample Variance145.860.005.700.4660.06102.579754446.10
Kurtosis3.070.081.086.326.2910.021.26−0.84
Skewness0.22−0.24−0.582.552.512.760.29−0.38
Range860.3713.813.5447257390
Minimum300.228.660.9101824
Maximum1160.5922.474.4549057594
Count193193193193193193192193
Confidence Level (95.0%)1.710.010.340.101.101.4414.063.00
Table 2. Comparison of stratified age groups.
Table 2. Comparison of stratified age groups.
Group12345p Value *
Number (N) per group2731543050
Age range (years)≤3031–4546–6061–75≥760.06
INR1.291.181.31.461.590.06
PT (seconds)14.9413.6314.9416.9218.20.06
APTT (seconds)29.4128.1631.4435.4329.30.04
Platelet count (×109/L)264.15241.94209.28227.13204.760.07
Sr. proteins (g/dL)67.6770.3570.7469.8363.70.003
HCT (%)39413936370.01
eWBV (mPas)15.8116.5316.415.8814.890.008
* Multivariate analysis.
Table 3. Comparison of gender groups.
Table 3. Comparison of gender groups.
VariablesGender GroupMeanStd. Deviationp Value
International normalization ratioF1.410.750.57
M1.350.59
Prothrombin timeF16.228.590.54
M15.526.77
Activated partial thromboplastin timeF30.9410.960.73
M30.429.22
Platelet countF240.2991.560.02
M206.04103.62
AgeF59.5020.740.24
M55.9621.28
Serum protein levelF66.3810.840.02
M70.3313.09
Haematocrit levelF0.380.060.07
M0.390.07
Estimated whole blood viscosityF15.452.240.01
M16.322.48
Table 4. Comparison of eWBV and haemostasis indices in dichotomous D-dimer groups.
Table 4. Comparison of eWBV and haemostasis indices in dichotomous D-dimer groups.
VariablesD-DimerMeanStd. Deviationp Value
International normalization rationo1.350.700.52
yes1.410.65
Prothrombin timeno15.628.270.59
yes16.237.08
Activated partial thromboplastin timeno29.257.450.03
yes32.5512.60
Platelet countno233.3972.310.13
yes211.65124.25
Ageno52.0619.670.001
yes65.1820.50
Serum protein levelno71.619.480.001
yes63.9813.71
Haematocrit levelno0.400.060.001
yes0.360.06
Estimated whole blood viscosityno16.671.790.001
yes14.832.66
Table 5. Summary of Pearson correlation eWBV and haemostasis indices.
Table 5. Summary of Pearson correlation eWBV and haemostasis indices.
INRPTAPTTPLT
International normalization ratio (INR)Correlation
Sig. (2-tailed)
Prothrombin time (PT seconds)Correlation0.992
Sig. (2-tailed)<0.001
Activated partial thromboplastin time (APTT seconds)Correlation0.4850.487
Sig. (2-tailed)<0.001<0.001
Platelet count (PLT 109.L)Correlation−0.127−0.112−0.114
Sig. (2-tailed)0.080.1230.116
Estimated whole blood viscosity (eWBV mPas)Correlation−0.17−0.15−0.120.26
Sig. (2-tailed)0.0170.0320.094<0.001
Table 6. Concordance among cases with repeat testing.
Table 6. Concordance among cases with repeat testing.
SexAgeD-DimereWBVPLTINRPTAPTT
1aM58Positive11.28881.11226
1bM58Positive11.15741.31428
2aM66Negative22.471071.31440
2bM66Negative20.59851.31441
3aF71Positive13.072731.41666
3bF71Positive9.522451.61837
4aM15Negative15.712581.11325
4bM15Negative16.452621.11327
5aF86Positive15.3921011125
5bF86Negative14.8720544445
6aM79Positive9.19531.21327
6bM79Positive9.59711.41532
7aM13Negative14.052081.21428
7bM13Negative15.542411.31428
8aF30Positive9.813011.71938
8bF30Positive13.265601.72035
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nwose, E.U.; Bwititi, P.T. Correlation Between Blood Coagulation Profile and Viscosity: Clinical Laboratory Observational Study. Med. Sci. 2025, 13, 20. https://doi.org/10.3390/medsci13010020

AMA Style

Nwose EU, Bwititi PT. Correlation Between Blood Coagulation Profile and Viscosity: Clinical Laboratory Observational Study. Medical Sciences. 2025; 13(1):20. https://doi.org/10.3390/medsci13010020

Chicago/Turabian Style

Nwose, Ezekiel U., and Phillip T. Bwititi. 2025. "Correlation Between Blood Coagulation Profile and Viscosity: Clinical Laboratory Observational Study" Medical Sciences 13, no. 1: 20. https://doi.org/10.3390/medsci13010020

APA Style

Nwose, E. U., & Bwititi, P. T. (2025). Correlation Between Blood Coagulation Profile and Viscosity: Clinical Laboratory Observational Study. Medical Sciences, 13(1), 20. https://doi.org/10.3390/medsci13010020

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop